Report      Database

    Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis - 2nd Edition

    Date: 05 Jul, 2017              Type: Vaccines              Pages: 199

    Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis - 2nd Edition
    • Electronic Access - Single User License
      $1,700.00
    • CD-ROM Mail Delivery
      $1,800.00
    • Hard-copy Mail Delivery
      $1,900.00
    • Electronic Access - Multi User License
      $2,500.00

    Get 10% Free Customization in this Report

    Global Pediatric Vaccines Market is expected to cross US$ 40 Billion by the year 2022. Our analysis found that the combination and pneumococcal vaccines was the two leading vaccines segment in 2017 and they continue to dominate the market in future years as well. The market of Combos (Combination vaccines) is thriving as most of the parents believed that if all these vaccines were given separately, than each child would have to take a large number of injections. 


    By the Year 2022, 500 Million Pediatrics will be get Immunization

    Our research found that around 500 million infants get immunization by the year 2022 owing to rising concern against vaccine-preventable diseases and growing awareness. This report covers the past and present scenario and the growth prospects of the infants’ vaccine (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap, Polio, Haemophilus influenzae type B, Rotavirus, Varicella, Combination) Vaccines market across the world for the period of 2011-2022.


    Globally 600 Million Doses of Vaccines will be Administrated in Pediatrics

    Our study indicates that that around the globe nearly 600 million doses of vaccines will be administrated in infants by the year 2022 which will be nearly five times the number of influenza doses administered. The number of DTap doses administered in infants is forecast to increase over the years and will cross 50 Million by the year 2022. Report covers detailed information on all the 11 vaccines (Pneumococcal, Rotavirus, Meningococcal, DTap, MMR, Polio, Hepatitis, Varicella, Haemophilus influenzae type B, Influenza, Combination) Vaccines Doses of Vaccines Administered and Forecast. 


    Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis is the 2nd edition report published by Renub Research on Pediatric Vaccines. This 199 page market research report with 93 Figures and 30 Tables provides data and analysis on Global Pediatric Vaccines Market, Infants Immunized, Number of Vaccine Doses Administered in Pediatric (Infant) (Disease wise) & Key Players. 

    Vaccine Has Been Extensively Studied From 3 Major Points    

    1.    Global Pediatric (Infant) Vaccines (Disease wise) Market & Forecast (2011 – 2022)

    2.    Pediatric (Infants) Immunized (Disease wise) & Forecast (2011 – 2022)

    3.    Doses of Vaccines Administered in Pediatric (Infant) (Disease wise) & Forecast (2011 – 2022)


    11 Vaccines Studied in the Report are as Follows
     
    1.    Influenza
    2.    MMR (Measles, Mumps, and Rubella)
    3.    Pneumococcal
    4.    Meningococcal
    5.    Hepatitis
    6.    DTap (Diphtheria, Tetanus, Pertussis)
    7.    Haemophilus influenzae type B
    8.    Polio
    9.    Rotavirus
    10.    Varicella
    11.    Combination Vaccine 

     

    Companies Vaccines Sales and Forecast 

    1. GlaxoSmithKline, plc Sales & Forecast (2011 – 2022)
    2. Merck & Co. Sales & Forecast (2011 – 2022)
    3. Sanofi Pasteur’s Sales & Forecast (2011 – 2022)
    4. Pfizer, Inc.’s Sales & Forecast (2011 – 2022)
    5. Others Vaccines

     

    Key Questions Answered In This Report

        What will be the market size of Global Pediatric Vaccine by the year 2022?

    •    What are the Key drivers for Pediatric Vaccines Market?

    •    What are the challenges to Infant Vaccines market?

    •    Who are the key players in Pediatric Vaccines market?

    •    What products are in key players Pipeline?

     

    Content from Old Report is given below:

    The user can buy this report in Chapters from Purchase by Chapter section given above

     

    Pediatric Vaccines Market Analysis
     
    Worldwide pediatric vaccine market has been growing rapidly over the last five years as it has doubled its market share in 2011 compared to 2005. The worldwide pediatrics vaccine market is expected to be more than US$ 23 Billion by 2015 growing with a single digit CAGR during 2012 – 2015. This incremental growth has been due to blockbuster vaccines (Prevnar7, Prevnar 13, Rotarix and Rotateq) sales in Billion of US$ which made a significant contribution. 
     
    It is predicted that Pediatric proprietary vaccines will lead the segment with little less than 60% market share by 2015.The combinations & boosters and enhanced pediatric vaccines market are expected to show stagnant growth in future due to lower margins and the mature nature of these markets. Pneumococcal, DTP and Varicella together all these three vaccines control 55% of the market share in 2011. 
     
    In number of cases Polio, Haemophiilus Influenzae Type B (HIB) and MMR cases have shown decline continuously from the year 2001 till 2011. Polio remains endemic merely in three countries and the good news is that India has not reported a single case from the past two years and on the verge of being called a polio free country.
     
    DTP are the most utilized vaccines in the pediatric vaccines market which contributed less than 10,000 Million doses in 2011. Pediatric Hepatitis and Polio vaccines are also mostly used vaccines which consumed more than 6,000 Million doses in 2011. In case of Rotavirus vaccine although the price of Rotavirus vaccine has declined but still its present prices are expensive than other pediatric vaccines. However despite all the impediments pediatric vaccines industry is expected to remain highly active in the future, fueled by the encouragement and financing from governments and other health organizations.      
    Renub Research report titled "Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis” talks about the pediatric vaccines. The report provides information on all the Nine (9) Pediatric Vaccines Market, Doses, Immunization and Number of Cases by region in the world. This report covers in detail all aspects of past, present and future scenario. This report provides market landscape and market share information of the Pediatric Combinations & Booster, Pediatric Enhanced Combination and Pediatric Proprietary Vaccines Market. The report also entails major factors driving the pediatric vaccine market and challenges of pediatric vaccine market. 
     
    Pediatric Vaccines Covered in this Report are as follows:
     
    Measles, Mumps & Rubella (MMR) Vaccines, Haemophilus Influenzae Type B (HIB) Vaccines, Polio Vaccines, Diphtheria, Tetanus & Pertussis (Combos) Vaccines, Pneumococcal Vaccines, Rotavirus Vaccines, Hepatitis Pediatric Vaccines, Varicella/Chicken Pox Vaccines and Other Pediatric Vaccines
     
    All the Pediatric Vaccines in this Report have been Studied from Four View Points:
     
    •  Number of Cases Reported for all 9 Pediatric Diseases by Region from 2001 to 2011
    •  Number of Doses Reported and Forecast for all 9 Pediatric Vaccine from 2005 to 2015
    •  Immunization Coverage for all 9 Pediatric Vaccines and Forecast from 2005 to 2015
    •  Market Size for all 9 Pediatric Vaccines and Forecast from 2005 to 2015 
     
    Key Topics Covered in the Report
     
    •  Worldwide – Pediatric Vaccines Market and Forecast (2006 - 2015)
    •  Worldwide – Pediatric Vaccines Market Share and Forecast (Sector wise) (2005 - 2015)
    •  Worldwide – Pediatric Vaccines Market Share &  Forecast (Disease wise) (2006 - 2015)
    •  By Sector (All 9) – Pediatric Vaccines Market and Forecast (2005 - 2015)
    •  By Region - Pediatric Disease Cases (2001 – 2011)
    •  Pediatric Vaccines Doses and Forecast (2005 – 2015)
    •  Pediatric Vaccines Immunization Coverage and Forecast (2005 - 2015)
    •  All 9 Pediatric Vaccines Market and Forecast (2005 - 2015)
    •  Growth Drivers of Pediatric Vaccines Market
    •  Challenges of Pediatric Vaccines Market
     
     
    Data Sources
     
    This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.
     
    Primary sources include industry surveys and telephone interviews with industry experts. 
     
    Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 100 paid databases.

    1.    Research Findings

    2.    Global - Pediatric (Infant) Vaccines Market and Forecast

    3.    Global – Pediatric (Infant) Vaccines Market Share and Forecast

    4.    Global – Pediatric (Infant) Immunized and Forecast

    5.    Global – Pediatric (Infant) Immunized Share and Forecast

    6.    Global – Doses of Pediatric (Infant) Vaccines Administered and Forecast

    7.    Global – Doses of Vaccines Administered to Pediatric (Infant) Share and Forecast

    8.    Global – Vaccine Companies Market Share and Forecast

    9.    Disease wise – Vaccines Market and Forecast
    9.1    Influenza – Pediatric (Infant) Vaccines Market and Forecast

    9.2    MMR (Measles, Mumps, and Rubella Vaccine) – Pediatric Vaccines Market and Forecast

    9.3    Pneumococcal – Pediatric Vaccines Market and Forecast

    9.4    Meningococcal – Pediatric Vaccines Market and Forecast

    9.5    Hepatitis – Pediatric Vaccines Market and Forecast

    9.6    DTaP – Pediatric Vaccines Market and Forecast

    9.7    Haemophilus Influenzae Type B (HIB) – Vaccines Market and Forecast

    9.8    Combos (Combination) – Vaccines Market and Forecast

    9.9    Polio – Vaccines Market and Forecast

    9.10    Rotavirus – Vaccines Market and Forecast

    9.11    Varicella – Vaccines Market and Forecast

     

    10.    Disease wise – Infants Immunized Numbers and Forecast
    10.1    Influenza – Number of Infants Immunized and Forecast

    10.2    MMR – Number of Pediatric (Infants) Immunized and Forecast

    10.3    Pneumococcal – Number of Infants Immunized and Forecast

    10.4    Meningococcal – Number of Infants Immunized and Forecast

    10.5    Hepatitis – Number of Infants Immunized and Forecast

    10.6    DTaP – Number of Infants Immunized and Forecast

    10.7    Hib (Haemophilus Influenzae Type B) – Number of Infants Immunized and Forecast

    10.8    Combos (Combination Vaccines) – Number of Infants Immunized and Forecast

    10.9    Polio – Number of Infants Immunized and Forecast

    10.10    Rotavirus – Number of Infants Immunized and Forecast

    10.11    Varicella – Number of Infants Immunized and Forecast

     

    11.    Disease wise – Doses of Vaccines Administered and Forecast
    11.1    Influenza – Doses of Infant Vaccines Administered and Forecast

    11.2    MMR – Doses of Infant Vaccines Administered and Forecast

    11.3    Pneumococcal – Doses of Infant Vaccines Administered and Forecast

    11.4    Meningococcal – Doses of Infant Vaccines Administered and Forecast

    11.5    Hepatitis – Doses of Infant Vaccines Administered and Forecast

    11.6    DTaP – Doses of Infant Vaccines Administered and Forecast

    11.7    Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered and Forecast

    11.8    Polio – Doses of Infant Vaccines Administered and Forecast

    11.9    Rotavirus – Doses of Infant Vaccines Administered and Forecast

    11.10    Varicella – Doses of Infant Vaccines Administered and Forecast

     

    12.    Disease wise - Immunization Profile
    12.1    Immunization Coverage (%) in Infants (2005 – 2015)

    12.2    Global Immunization Profile (2011 – 2015)

    12.3    Regional Immunization Profile (2001 – 2015)
    12.3.1    Measles – Number of Cases Reported
    12.3.2    Mumps – Number of Cases Reported
    12.3.3    Rubella – Number of Cases Reported
    12.3.4    Rubella (CRS) – Number of Cases Reported
    12.3.5    Diphtheria – Number of Cases Reported
    12.3.6    Tetanus (Neonatal) – Number of Cases Reported
    12.3.7    Tetanus (Total) – Number of Cases Reported
    12.3.8    Pertussis – Number of Cases Reported
    12.3.9    Polio – Number of Cases Reported
    12.3.10    Yellow Fever – Number of Cases Reported
    12.3.11    Japanese encephalitis – Number of Cases Reported, 2006 - 2015

    13.    Vaccines Key Players Sales and Forecast
    13.1    GlaxoSmithKline, plc.’s Vaccines Sales and Forecast

    13.2    Merck & Co. Vaccines Sales and Forecast

    13.3    Sanofi Pasteur’s Vaccines Sales and Forecast

    13.4    Pfizer, Inc.’s Vaccines Sales and Forecast

    13.5    Others Vaccines Sales and Forecast

    14.    Vaccines – Products and Pipeline
    14.1    GSK Vaccine Product Pipeline

    14.2    Merck Vaccine Product Pipeline

    14.3    Sanofi Vaccine Product Pipeline

    14.4    Pfizer Vaccine Product Pipeline

     

    15.    Top Mergers and Acquisitions in the Vaccine Industry

     

    16.    Vaccines and Regulator’s Interventions
    16.1    Making and Meeting Standards of Quality and Safety

    16.2    Vaccine Funding

     

    17.    Vaccine Market Drivers
    17.1    Inclusion in National Immunization Schedule

    17.2    Growing Immunization Coverage for HPV Vaccines

    17.3    Increase in Prevalence of Infectious Diseases

    17.4    Global Immunization Vision and Strategy (GIVS)

    17.5    GAVI Model Fuelling Vaccine Manufacturers
    17.5.1    The Partnership Model
    17.5.2    The Business Model

    17.6    Increasing Vaccine Availability in United States

    17.7    The Vaccine Safety Data link Project

    17.8    The Vaccine Injury Compensation Program

    17.9    Transforming of Vaccine Technologies

    17.10    Global Vaccine Action Plan by WHO (2011 - 2020)

    17.11    Continuous Focus on Effective Communication Strategies

     

    18.    Vaccines Market Challenges
    18.1    Hurdles to Optimal use of Licensed Vaccines
    18.1.1    Technical Obstacles
    18.1.2    Economic Obstacles
    18.1.3    Cultural Obstacles

    18.2    Complexity of Vaccine Development & Approval System Thwarts Product Development
    18.2.1    Legal Obstacles
    18.2.2    General Technical Barriers
    18.2.3    Economic Barriers
    18.2.4    Regulatory Barriers

    18.3    Shortening the Timeline for Vaccine Development

    18.4    Refusal/Resistance to Vaccination
    18.4.1    Vaccine Adverse Event Reporting System

    18.5    Vaccine Shortages and Delays

    18.6    Obstacles in Vaccine Research & Development

    18.7    Barriers to New Entrants in the Vaccines Market

    List of Figures

    Figure 2‑1: Global – Pediatric (Infant) Vaccines Market (Billion US$), 2011 – 2016
    Figure 2‑2: Global – Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2017 – 2022

    Figure 4‑1: Global – Pediatric (Infant) Immunized (Million), 2011 - 2016
    Figure 4‑2: Global – Forecast for Pediatric (Infant) Immunized (Million), 2017 – 2022

    Figure 6‑1: Global – Doses of Pediatric (Infant) Vaccines Administered (Million), 2011 - 2016
    Figure 6‑2: Global – Forecast for Doses of Pediatric (Infant) Vaccines Administered (Million), 2017 - 2022

    Figure 8‑1: Global – Key Players Vaccines Market Share (Percent), 2011 - 2016
    Figure 8‑2: Global – Forecast for Key Players Vaccines Market Share (Percent), 2017 - 2022

    Figure 9‑1: Influenza – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
    Figure 9‑2: Influenza – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
    Figure 9‑3: MMR – Pediatric (Infant) Vaccines Market (Million US$), 2011 – 2016
    Figure 9‑4: MMR – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
    Figure 9‑5: Pneumococcal – Pediatric (Infant) Vaccines Market (Billion US$), 2011 - 2016
    Figure 9‑6: Pneumococcal – Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2017 - 2022
    Figure 9‑7: Areas with frequent epidemics of meningococcal meningitis
    Figure 9‑8: Meningococcal – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
    Figure 9‑9: Meningococcal – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
    Figure 9‑10: Hepatitis – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
    Figure 9‑11: Hepatitis – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
    Figure 9‑12: DTaP – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
    Figure 9‑13: DTaP – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
    Figure 9‑14: Haemophilus Influenzae Type B (HIB) – Vaccines Market (Million US$), 2011 - 2016
    Figure 9‑15: Haemophilus Influenzae Type B (HIB) – Forecast for Vaccines Market (Million US$), 2017 - 2022
    Figure 9‑16: Combos (Combination) – Vaccines Market (Billion US$), 2011 - 2016
    Figure 9‑17: Combos (Combination) – Forecast for Vaccines Market (Billion US$), 2017 - 2022
    Figure 9‑18: Polio – Vaccines Market (Million US$), 2011 - 2016
    Figure 9‑19: Polio – Forecast for Vaccines Market (Million US$), 2017 - 2022
    Figure 9‑20: Rotavirus Deaths Under Five Years of Age per 100 000 Population <5 Years of Age, 2013
    Figure 9‑21: Ten Countries Accounting for Almost Two Thirds of All Deaths, 2013
    Figure 9‑22: Rotavirus – Vaccines Market (Million US$), 2011 - 2016
    Figure 9‑23: Rotavirus – Forecast for Vaccines Market (Million US$), 2017 - 2022
    Figure 9‑24: Varicella – Vaccines Market (Billion US$), 2011 - 2016
    Figure 9‑25: Varicella – Forecast for Vaccines Market (Billion US$), 2017 – 2022

    Figure 10‑1: Influenza – Number of Infants Immunized (Thousand), 2011 - 2016
    Figure 10‑2: Influenza – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
    Figure 10‑3: MMR – Number of Pediatric (Infants) Immunized (Thousand), 2011 - 2016
    Figure 10‑4: MMR – Forecast for Number of Pediatric (Infants) Immunized (Thousand), 2017 - 2022
    Figure 10‑5: Pneumococcal – Number of Infants Immunized (Thousand), 2011 - 2016
    Figure 10‑6: Pneumococcal – Forecast for Number of Infants Immunized (Thousand), 2011 - 2016
    Figure 10‑7: Meningococcal – Number of Infants Immunized (Thousand), 2011 - 2016
    Figure 10‑8: Meningococcal – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
    Figure 10‑9: Hepatitis – Number of Infants Immunized (Thousand), 2011 - 2016
    Figure 10‑10: Hepatitis – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
    Figure 10‑11: DTaP – Number of Infants Immunized (Thousand), 2011 - 2016
    Figure 10‑12: DTaP – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
    Figure 10‑13: Hib (Haemophilus Influenzae Type B) – Number of Infants Immunized (Million), 2011 - 2016
    Figure 10‑14: Hib (Haemophilus Influenzae Type B) – Forecast for Number of Infants Immunized (Million), 2017 - 2022
    Figure 10‑15: Combos (Combination Vaccines) – Number of Infants Immunized (Million), 2011 - 2016
    Figure 10‑16: Combos (Combination Vaccines) – Forecast for Number of Infants Immunized (Million), 2017 - 2022
    Figure 10‑17: Polio – Number of Infants Immunized (Million), 2011 - 2016
    Figure 10‑18: Polio – Forecast for Number of Infants Immunized (Million), 2017 - 2022
    Figure 10‑19: Rotavirus – Number of Infants Immunized (Million), 2011 - 2016
    Figure 10‑20: Rotavirus – Forecast for Number of Infants Immunized (Million), 2017 - 2022
    Figure 10‑21: Varicella – Number of Infants Immunized (Million), 2011 - 2016
    Figure 10‑22: Varicella – Forecast for Number of Infants Immunized (Million), 2017 - 2022

    Figure 11‑1: Influenza – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 11‑2: Influenza – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 11‑3: MMR – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 11‑4: MMR – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 11‑5: Pneumococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 11‑6: Pneumococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 11‑7: Meningococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 11‑8: Meningococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 11‑9: Hepatitis – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 11‑10: Hepatitis – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 11‑11: DTaP – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 11‑12: DTaP – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 11‑13: Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 11‑14: Hib (Haemophilus Influenzae Type B) – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 11‑15: Polio – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 11‑16: Polio – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 11‑17: Rotavirus – Doses of Infant Vaccines Administered (Million), 2011 – 2016
    Figure 11‑18: Rotavirus – Forecast for Doses of Infant Vaccines Administered (Million), 2017 – 2022
    Figure 11‑19: Varicella – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 11‑20: Varicella – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022

    Figure 12‑1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
    Figure 12‑2: Worldwide Immunization Coverage (%) in Infants, 2011- 2015

    Figure 13‑1: GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2011 - 2016
    Figure 13‑2: Forecast for GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2017 - 2022
    Figure 13‑3: Merck & Co. Vaccines Sales (Billion US$), 2011 - 2016
    Figure 13‑4: Worldwide – Forecast for Merck & Co. Vaccines Sales (Billion US$), 2017 - 2022
    Figure 13‑5: Sanofi Pasteur’s Vaccines Sales (Billion US$), 2011 - 2022
    Figure 13‑6: Forecast for Sanofi Pasteur’s Vaccines Sales (Billion US$), 2017 - 2022
    Figure 13‑7: Pfizer, Inc.’s Vaccines Sales (Billion US$), 2011 - 2016
    Figure 13‑8: Forecast for Pfizer, Inc.’s Vaccines Sales (Billion US$), 2017 - 2022
    Figure 13‑9: Others Vaccines Sales (Billion US$), 2011 - 2016
    Figure 13‑10: Forecast for Others Vaccines Sales (Billion US$), 2017 - 2022

    Figure 14‑1: GSK Vaccine Product Pipeline

    Figure 17‑1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
    Figure 17‑2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
    Figure 17‑3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
    Figure 17‑4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
    Figure 17‑5: US Retail Clinics Expected to Surge by 2017


    Lists of Tables

    Table 3‑1: Global – Pediatric (Infant) Vaccines Market Share (Percent), 2011 - 2016
    Table 3‑2: Global – Forecast for Pediatric (Infant) Vaccines Market Share (Percent), 2017 - 2022

    Table 5‑1: Global – Pediatric (Infant) Immunized Share (Percent), 2011 – 2016
    Table 5‑2: Global – Forecast for Pediatric (Infant) Immunized Share (Percent), 2017 – 2022

    Table 7‑1: Global – Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2011 - 2016
    Table 7‑2: Global – Forecast for Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2017 - 2022

    Table 12‑1: Worldwide – Number of Reported Cases, 2011 – 2015
    Table 12‑2: Measles – Number of Cases Reported, 2001 – 2015
    Table 12‑3: Mumps – Number of Cases Reported, 2001 - 2015
    Table 12‑4: Rubella – Number of Cases Reported, 2001 - 2015
    Table 12‑5: Rubella (CRS) – Number of Cases Reported, 2001 - 2015
    Table 12‑6: Diphtheria – Number of Cases Reported, 2001 - 2015
    Table 12‑7: Tetanus (Neonatal) – Number of Cases Reported, 2001 – 2015
    Table 12‑8: Tetanus (Total) – Number of Cases Reported, 2001 - 2015
    Table 12‑9: Pertussis – Number of Cases Reported, 2001 - 2015
    Table 12‑10: Polio – Number of Cases Reported, 2001 - 2015
    Table 12‑11: Yellow Fever – Number of Cases Reported, 2001 - 2015
    Table 12‑12: Japanese encephalitis – Number of Cases Reported, 2006 - 2015

    Table 14‑1: Merck Vaccine Product Pipeline
    Table 14‑2: Sanofi Vaccine Product Pipeline
    Table 14‑3: Pfizer Vaccine Product Pipeline

    Table 15‑1: Vaccine Mergers & Acquisitions

    Table 17‑1: United States Immunization Schedule
    Table 17‑2: Afghanistan Immunization Schedule
    Table 17‑3: Norway Immunization Schedule
    Table 17‑4: India Immunization Schedule
    Table 17‑5: Vietnam Immunization Schedule
    Table 17‑6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
    Table 17‑7: Goal-Level Indicators, 2015 & 2020
    Table 17‑8: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations

    • Description
      Price
    • Chapter 1 & 2     Pages : 20
      $300
    • Chapter 3     Pages : 2
      $300
    • Chapter 4     Pages : 2
      $300
    • Chapter 5     Pages : 5
      $300
    • Chapter 6.1     Pages : 8
      $200
    • Chapter 6.2     Pages : 7
      $200
    • Chapter 6.3     Pages : 6
      $200
    • Chapter 6.4     Pages : 8
      $200
    • Chapter 6.5     Pages : 10
      $200
    • Chapter 6.6     Pages : 8
      $200
    • Chapter 6.7     Pages : 8
      $200
    • Chapter 6.8     Pages : 4
      $200
    • Chapter 6.9     Pages : 2
      $200
    • Chapter 7     Pages : 16
      $250
    • Chapter 8     Pages : 7
      $250

    Related Products